MedPath
FDA Approval

PEDMARK

FDA-approved pharmaceutical product with comprehensive regulatory information, manufacturing details, and complete labeling documentation.

FDA Approval Summary

Company
Effective Date
September 30, 2022
Labeling Type
HUMAN PRESCRIPTION DRUG LABEL
Sodium Thiosulfate(12.5 g in 100 mL)

Manufacturing Establishments6

FDA-registered manufacturing facilities and establishments involved in the production, packaging, or distribution of this drug product.

Cambrex Agawam MA

Fennec Pharmaceuticals Inc.

079509111

SGS Life Science Services

Fennec Pharmaceuticals Inc.

049859261

Cambrex Durham, NC

Fennec Pharmaceuticals Inc.

108353231

Cambrex Charles City, Inc.

Fennec Pharmaceuticals Inc.

782974257

Berkshire Sterile Manufacturing

Fennec Pharmaceuticals Inc.

079589218

A+ Secure Packaging LLC, d/b/a Cardinal Health Packaging

Fennec Pharmaceuticals Inc.

963589036

Products1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

PEDMARK

Product Details

NDC Product Code
73077-010
Application Number
NDA212937
Marketing Category
NDA (C73594)
Route of Administration
INTRAVENOUS
Effective Date
September 30, 2022
BORIC ACIDInactive
Code: R57ZHV85D4Class: IACT
Code: HX1032V43MClass: ACTIMQuantity: 12.5 g in 100 mL
SODIUM HYDROXIDEInactive
Code: 55X04QC32IClass: IACT
HYDROCHLORIC ACIDInactive
Code: QTT17582CBClass: IACT
© Copyright 2025. All Rights Reserved by MedPath